Prevalence of the Direct Antiglobulin Test and Its Clinical Impact on Multiply Transfused Thalassemia Patients: A Prospective Study Conducted at a Tertiary Care Center in Northern India

Lab Med. 2023 Jul 5;54(4):406-410. doi: 10.1093/labmed/lmac140.

Abstract

Objective: This study was conducted to estimate prevalence of direct antiglobulin test (DAT) positivity and its impact on transfusion support in patients with thalassemia.

Methods: The DAT testing was performed for patients with β-thalassemia who received transfusion from November 2021 to March 2022. Elution was done for DAT-positive samples.

Results: Of 180 patients, 21 (11.6%) were DAT positive. Immunoglobulin G (IgG) was present in 4 (19%) and IgG+C3d was present in 8 (38%). Only complement was present in 9 (42.8%) patients. The IgG-reactive DATs were associated with pan-reactive eluate. Patients who were DAT-positive had significantly higher levels of serum bilirubin, ferritin, and IgG than those who were DAT-negative.

Conclusion: Autoantibody formation in multiply transfused thalassemia patients is common and merits equal attention as alloimmunization. It is particularly important as DAT-positive red blood cells may undergo clinically significant hemolysis, which may increase the transfusion requirements with associated sequalae such as increased serum ferritin and splenomegaly.

Keywords: DAT; IgG; auto antibody; ether elution; hepatitis C; serum ferritin; splenectomy; β thalassemia.

MeSH terms

  • Coombs Test
  • Humans
  • Immunoglobulin G
  • India / epidemiology
  • Prevalence
  • Prospective Studies
  • Tertiary Care Centers
  • Thalassemia* / epidemiology
  • Thalassemia* / therapy

Substances

  • Immunoglobulin G